Health & Environmental Research Online (HERO)


Print Feedback Export to File
2733543 
Journal Article 
Fluconazole treatment for vulvovaginal candidiasis during pregnancy 
Campomori, A; Bonati, M 
1997 
Yes 
Annals of Pharmacotherapy
ISSN: 1060-0280
EISSN: 1542-6270 
IPA/97/1122021 
Pharmacother 
REF 5 
118-119 
English 
IPA COPYRIGHT: ASHP An increase in the number of inquiries to one regional drug information center about fetal risks after exposure to fluconazole for the treatment of vaginal candidiasis led to a follow-up of 16 pregnant callers who agreed to answer a telephone interview 1 month after delivery to examine for possible teratogenic effects of fluconazole therapy during pregnancy. Their mean gestational weight gain was 12.9 kg. Besides 1 set of twins, who were stillborn, but not malformed, these women delivered 15 babies, 11 by vaginal birth and 4 by cesarean section. It was calculated that the average fluconazole intake was 291 mg (range 150-1000), starting at 4 wk of gestation and therapy lasted 1 wk. At follow up, none of the 15 infants showed any malformation or perinatal pathologic symptoms, which led to the conclusion that the duration of therapy, the daily dosage, and the diseases are essential factors related to potential malformation. A single dose of 150 mg oral fluconazole is proposed as a convenient, safe, and effective treatment for vulvovaginal candidiasis in pregnancy.